

REMARKS

Claims 1-4, 6-11 and 13 are pending in the application. Claims 1-8, 10 and 11 are rejected. Claims 9 and 13 are objected to. Claim 12 is herein canceled.

Objections to the Specification

The Examiner objects to the amendment filed 6/30/03 as introducing new matter. Applicants respectfully disagree with this objection. Applicants note that this is not a new matter because it is a mere translational error. Applicants note that this is disclosed in the priority Japanese specification on page 4, lines 21 to 23 in WO 00/40654, filed on December 28, 1999.

Claim Rejections - 35 U.S.C. §102

Claims 1-4 and 10 are rejected under 35 U.S.C. §102(b) as being anticipated by Yukimoto et al. (U.S. Patent No. 4,906,707) as exemplified by Takago et al. (U.S. Patent No. 4,323,488).

Applicants herein amend claim 1, and subsequently respectfully disagree with the Examiner's rejection because not all of the claimed limitations are taught or suggested by the cited reference.

Applicants herein amend claim 1 is to change "not less than 85%" to read "not less than 90%". Applicants note that Yukimoto et al. does not teach an introduction rate above 85%. Applicants further note that there would have been no motivation to enhance the introduction rate of the reactive silicon group into molecular terminus to 90% or more.

Therefore, Applicants submit that the present amendment has overcome the rejection, and request its withdrawal.

Claim Rejections - 35 U.S.C. §103

Claims 6-8 are rejected under 35 U.S.C. §103(a) as being unpatentable over Yukimoto et al. (U.S. Patent No. 4,906,707) and exemplified by Takago et al. (U.S. Patent No. 4,323,488) as applied to claim 1 above and further in view of Higuchi et al. (U.S. Patent No. 5,223,583).

The Examiner concludes that it would have been obvious to use a methyl group for R³ and a methylene group for R⁴, because Yukimoto et al. expressly provides for these groups as set forth above.

As noted above, Applicants herein amend claim 1 to include further supported limitations. Further as noted above, Applicants submit that the present amendment has overcome the above rejection of claims 1-4 and 6-10. Because claims 6-8 are dependent from and necessarily include the limitations of claim 1, Applicants submit that the rejection to claims 6-8 has been overcome as well.

Claim 11 is rejected under 35 U.S.C. §103(a) as being unpatentable over Yukimoto et al. and exemplified by Takago et al. as applied to claim 1 above and further in view of Hattori et al. (EP 0 856 569).

The Examiner concludes that it would have been obvious to use the polymers of Yukimoto in the direct-glazing method set forth by Hattori et al., because it is known to select a known material based on its suitability for its intended uses.

As noted above, Applicants herein amend claim 1 to include further supported limitations. Further as noted above, Applicants submit that the present amendment has overcome the above rejection of claim 1. Because claim 11 is dependent from and necessarily include the limitations of claim 1, Applicants submit that the rejection to claim 11 has been overcome as well.

Response under 37 C.F.R. §1.111
Attorney Docket No. 010794
Serial No. 09/868,657


In view of the aforementioned amendments and accompanying remarks, Applicants submit that the claims, as herein amended, are in condition for allowance. Applicants request such action at an early date.

If the Examiner believes that this application is not now in condition for allowance, the Examiner is requested to contact Applicants' undersigned attorney to arrange for an interview to expedite the disposition of this case.

If this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. The fees for such an extension or any other fees that may be due with respect to this paper may be charged to Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP


Kenneth H. Salen
Attorney for Applicants
Registration No. 43,077

KHS/led
1250 Connecticut Avenue, NW
Suite 700
Washington, D.C. 20036
(202) 822-1100

Q:\2001\010794\010794 Amendment 12-17-03.doc